EUVIMEDAvasta EUVIMED
CrossrefInfokaart

Structural insights into tyrosine sulfation of CCR5 by human tyrosylprotein sulfotransferase‐1

Shinnosuke Tanaka, Hirai Asano, Kota Toyoda, Toshiaki Nishiyori, Hidetaka Kojo, Kazuto Kiyomatsu, Katsuhisa Kurogi, Yoichi Sakakibara, Etsuko Nishimoto, Takamasa Teramoto, Yoshimitsu Kakuta

The FEBS Journal · 2026-11 · 293 (21) · 6552-6568

DOI: 10.1111/febs.70597 ↗
AbstraktBibliograafilised andmed

Abstrakt

Post‐translational sulfation of the chemokine receptor CCR5 is involved in crucial biological processes such as viral infection and chemokine signaling. This sulfation can occur at the N‐terminal tyrosine residues (Y3, Y10, Y14, and Y15) of CCR5 and is catalyzed by human tyrosylprotein sulfotransferases (hTPSTs) within the Golgi lumen. However, the detailed molecular mechanism by which these tyrosine residues are sulfated remains unresolved. To elucidate the mechanism, we determined the crystal structure of a soluble domain of hTPST1 bound to the sulfate donor product 3′‐phosphoadenosine 5′‐phosphate (PAP) and a modified 18‐residue CCR5 peptide designed to isolate the Y3‐centered binding mode, at 3.2 Å resolution, with six peptide residues ordered. This structure defines key interactions consistent with Y3 sulfation and is consistent with previous biochemical data. Based on the crystal structure and prior knowledge, we constructed peptide docking models for Y10, Y14, and Y15 sulfation, as well as full‐length hTPST1‐PAP‐CCR5 docking models. The crystal structure provides experimental insight into Y3 recognition, whereas the docking models provide testable hypotheses for how the other sulfation sites may be accommodated in the context of CCR5.

Teadmised, mis sobivad teie tööga.

Tasuta alustamisest ja isiklikust kirjanduse otsingust kuni täieliku Research Suite’ini.

Vaata pakette →

Kas kõik kirjastajate täistekstid on kaasatud?

Ei. Bibliograafilised kirjed, kokkuvõtted ja täistekstid on erinevad sisud. See, kas täistekst on saadaval, sõltub allikast, Open Accessist ja teie olemasolevatest litsentsidest. EUVIMED-i pakett ei asenda täiendavaid kirjastajaõigusi.

Vaata pakette →